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Abstract
Obesity is recognized as a global health crisis. Bariatric
surgery offers a treatment that can reduce weight,
induce remission of obesity-related diseases, and
improve the quality of life. In this article, we outline
the different options in bariatric surgery and
summarize the recommendations for selecting and
assessing potential candidates before proceeding to
surgery. We present current data on post-surgical
outcomes and evaluate the psychosocial and
economic effects of bariatric surgery. Finally, we
evaluate the complication rates and present
recommendations for post-operative care.
Keywords: Bariatric surgery, obesity, pre-operative
assessment, postoperative outcomes.
Background
The rates of obesity are increasing with at least 300 mil-
lion people worldwide now classified as obese [1]. Obe-
sity is associated with reduced life expectancy, increased
morbidity and mortality, and greater healthcare costs
[2,3]. Bariatric surgery is more effective than non-surgical
treatments of obesity with a reduction in overall mortal-
ity of 30% demonstrated in surgical recipients [4-7].
Greater reductions are seen in cancer and diabetes mor-
tality [6,7].
Recommendations for referring candidates for baria-
tric surgery are available but they seldom give guidance
to help a specific patient. We will examine the evidence
for the magnitude and duration of the positive effects
and negative side effects of bariatric surgery. Finally, we
will offer a synopsis of the data on post-operative




Available options in bariatric surgery
Several bariatric procedures are available. The most
commonly performed procedures are Roux-en-Y gastric
bypass (RYGB), adjustable gastric banding (AGB), and
sleeve gastrectomy (SG) [8]. Biliopancreatic diversion,
with or without duodenal switch (BPD and BPD-DS), is
less commonly performed but is often considered in
extremely obese individuals [9]. All procedures can be
performed laparoscopically with a lower rate of compli-
cations such as wound infection and incisional hernias
[10].
In RYGB, the stomach is divided into an upper gastric
pouch, which is 15 to 30 mL in volume and a lower gastric
remnant. The gastric pouch is anastomosed to the jeju-
num after it has been divided some 30 to 75 cm distal to
the ligament of Treitz; this distal part is brought up as a
‘Roux-limb’. The excluded biliary limb, including the gas-
tric remnant, is connected to the bowel some 75 to 150
cm distal to the gastrojejunostomy (see Figure 1).
In AGB, a band with an inner inflatable silastic balloon
is placed around the proximal stomach just below the
gastroesophageal junction. The band can be tightened
through a subcutaneous access port by the injection or
withdrawal of a saline solution [11] (see Figure 2).
In SG, the stomach is transected vertically over a 34 or
36F bougie creating a gastric tube and leaving a pouch of
100 to 200 mL (see Figure 3). Although many regard SG
as a restrictive procedure, it is increasingly recognized as
a metabolic procedure [12].
BPD involves a partial gastrectomy that results in a 400
mL gastric pouch [13]. The small bowel is divided 250 cm
proximal to the ileocecal valve, and the alimentary limb is
connected to the gastric pouch to create a Roux-en-Y
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Figure 1 RYGB: Roux-en-Y gastric bypass. An upper gastric pouch, of 15 to 30 mL in volume, and a lower gastric remnant is formed from the
stomach. The jejunum is divided some 30 to 75 cm distal to the ligament of Treitz, and anastomosed to the gastric pouch. The distal jejunum is
brought up as a ‘Roux-limb’. The excluded biliary limb, including the gastric remnant, is anastomosed to the bowel some 75 to 150 cm distal to
the gastrojejunostomy. The included figures are the property of Johnson and Johnson and Ethicon Endo-Surgery (Europe). They are reproduced
here with their kind permission.
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Figure 2 AGB: Adjustable gastric band. A band with an inner inflatable silastic balloon is placed around the proximal stomach just below
the gastroesophageal junction. The band is adjusted through a subcutaneous access port by the injection or withdrawal of solution. The
included figures are the property of Johnson and Johnson and Ethicon Endo-Surgery (Europe). They are reproduced here with their kind
permission.
Neff et al. BMC Medicine 2013, 11:8
http://www.biomedcentral.com/1741-7015/11/8
Page 3 of 17
Figure 3 SG: Sleeve gastrectomy. The stomach is transected vertically creating a gastric tube and leaving a pouch of 100 to 200 mL. The
included figures are the property of Johnson and Johnson and Ethicon Endo-Surgery (Europe). They are reproduced here with their kind
permission.
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gastroenterostomy. An anastomosis is performed between
the excluded biliopancreatic limb and the alimentary limb
50 cm proximal to the ileocecal valve (see Figure 4). In
BPD-DS, a vertical SG is constructed and the division of
the duodenum is performed immediately beyond the
pylorus. The alimentary limb is connected to the duode-
num, whereas the iliopancreatic limb is anastomosed to
the ileum 75 cm proximal to the ileocecal valve [14].
Endoscopically placed synthetic duodenojejunal bypass
liners such as the EndoBarrier® have been recently
developed and are associated with a mean weight loss of
10% to 20% [15,16]. These devices establish duodenal
exclusion and result in greater weight loss than diet and
exercise alone up to 12 weeks post-insertion [17]. They
may also improve glycemic control in those with type 2
diabetes mellitus (T2DM) [18].
However, long-term data remain to be reported and
the device is often poorly tolerated [18]. Complications
include sleeve migration and obstruction, which can
occur with a frequency of 15% to 20% [15,16,18]. It can
also be difficult to insert the device with placement fail-
ure in up to 13% [18]. While the concept of endoscopic
techniques such as Endobarrier® remains attractive, the
permanence of the weight loss and the clinical role of
the device itself remain to be determined.
Other techniques for the treatment of obesity include
the intra-gastric balloon, which can be effective for
short-term weight loss [16]. However, these newer tech-
niques remain in the experimental realm and data on
long-term clinical efficacy are not available. The Endo-
Barrier® may not be any better or worse than gastric
balloons or very low calorie diets at reducing operative
risk in patients with extreme obesity. The device may be
developed for use in those with diabetes and obesity
who decline laparoscopic bariatric surgery. If other non-
surgical treatments such as exogenous satiety gut hor-
mones, or weight loss maintenance diets, can show that
the weight loss after removal of the EndoBarrier® can
be maintained, then a comparison with established bar-
iatric procedures may be feasible.
Candidate selection and pre-operative assessment
Patient selection criteria for bariatric surgery include
body mass index (BMI), the presence of co-morbidities
and a history of prior weight loss attempts. National
Institute of Clinical Excellence (NICE) and National
Institutes of Health (NIH) guidelines state that bariatric
surgery should be offered to patients with a BMI of 35
to 40 kg/m2 who have obesity related conditions such as
diabetes mellitus or obstructive sleep apnea, or in those
with a BMI of 40 kg/m2 or greater regardless of weight
related co-morbidities [19,20]. Bariatric surgery for indi-
viduals with a BMI less than 35 kg/m2 with obesity
related co-morbidities is under investigation but is not
currently recommended [21].
If a candidate meets the criteria for surgery, then a
multi-disciplinary team assessment is made as to the
suitability of the candidate. This is a complex process
involving psychological, surgical, dietetic and medical
review. The individual must be physically and psycholo-
gically fit to proceed to surgery. Expectations must be
managed and a determination must be made as to the
individuals’ ability to comply with post-operative care.
The decision to operate will take into account the bene-
fits the candidate is likely to gain, and the risks peri-
operatively and post-operatively.
This is an individualized assessment, and the role of
the psychologist and/or psychiatrist should be central.
Some reports suggest an increased risk of suicide after
bariatric surgery, although the etiology remains unclear
[6]. Major failures of bariatric surgery are due to poor
psychological adaptation, especially if the patient’s
expectations were not adequately managed. All candi-
dates should be given the correct and realistic informa-
tion on what the procedure can achieve. If this is
addressed, then the risk of surgical failure can often be
mitigated [22,23]. This personalized assessment is a vital
part of the pre-operative assessment.
For each patient the benefits of the procedure should
outweigh the operative risk. In general, obese patients
have an increased prevalence of cardiopulmonary dis-
ease that may be undiagnosed pre-operatively [24]. An
individualized pre-operative assessment should be com-
pleted by a multi-disciplinary team [25]. Pre-operative
investigations should focus on screening for cardiac
arrhythmia, prolonged QT syndrome, and cardiomyopa-
thy [25]. Almost 70% of individuals awaiting bariatric
surgery can be diagnosed with obstructive sleep apnea,
with over 40% meeting the criteria for severe disease
[26,27]. However, this is not associated with a greater
rate of peri-operative complications [28]. Male gender,
age older than 50 years, congestive heart failure, periph-
eral vascular disease and renal impairment are asso-
ciated with greater mortality [29].
Predicting outcomes
Once the candidate has been selected, then the appropri-
ate procedure must be chosen. Unfortunately, there is no
evidence based medical approach for procedure selection,
and this remains one of the most frustrating shortfalls in
bariatric practice for clinicians and patients. Clinicians
take a pragmatic approach to the choice of procedure,
and the decision is determined by the individuals’ clinical
phenotype, the aims of therapy, and peri-operative risk.
Clinicians and patients can often be disappointed
when surgical outcomes are not as impressive as may
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Figure 4 BPD: Biliopancreatic diversion. A 400 mL gastric pouch is formed from the stomach. The small bowel is divided 250 cm proximal to
the ileocecal valve and is connected to the gastric pouch to create a Roux-en-Y gastroenterostomy. An anastomosis is performed between the
excluded biliopancreatic limb and the alimentary limb 50 cm proximal to the ileocecal valve. In BPD-DS, a vertical sleeve gastrectomy is
constructed and the division of the duodenum is performed immediately beyond the pylorus. The alimentary limb is connected to the
duodenum, whereas the iliopancreatic limb is anastomosed to the ileum 75 cm proximal to the ileocecal valve. The included figures are the
property of Johnson and Johnson and Ethicon Endo-Surgery (Europe). They are reproduced here with their kind permission.
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have been hoped and look for objective evidence that
can allow them to predict outcomes. The most dama-
ging outcome of surgical procedures that do not per-
form as expected is to blame the recipient for not
performing well enough with regard to diet and exercise,
when in fact, the failure is almost always rooted in biol-
ogy. Weight loss prediction is one of the common aims
of these predictive models. Pre-operative weight loss can
predict post-operative weight loss, putatively as a marker
of ‘intrinsic motivation’ [30,31]. These data are conten-
tious and not without bias as many of them are retro-
spective uncontrolled studies [32]. The available
prospective data are of short duration [31,32]. A sys-
tematic review shows that 50% of the published results
find that pre-operative weight loss has an association
with weight change post-operatively, and the remaining
50% refute these findings [32]. In the context of this evi-
dence, pre-operative weight loss cannot be relied on to
predict surgical outcomes at this time.
Genetic disorders such as melanocortin-4 receptor
(MC4R) deficiency may have an inherent physiological
role in these mixed results, as animals with MC4R defi-
ciency have a resistance to weight loss after bariatric
surgery [33]. There is interest in these genotypes, as
identifying them may aid the prediction of outcomes.
However, identified phenotypes such as MC4R are not
common in the obese population, with heterogeneous
mutations identified in less than 3% of European and
North American obese cohorts [34]. Culprit genes that
have been associated with obesity, with approximately
20 implicated to date, are still only found in 5% of obese
people [35].
Investigation of genetic factors that may predict indivi-
dual responses to bariatric surgery is ongoing and contro-
versial [35-37]. While certain genotypes are associated
with improved outcomes after bariatric surgery, they are
not procedure specific and, therefore, while potentially
aiding prediction of weight loss post-operatively, will not
aid procedure selection [35-37]. It is also well recognized
that the genetic influence on obesity may be much more
complex than we currently understand, with the inevitable
influence of environment making the situation less clear.
For now, study of identified genotypes, with a correlation
between genotype and treatment outcomes, may answer
questions on the clinical utility and predictive ability of
genotyping in bariatric surgery [33].
To date, any potential genetic markers or biomarkers of
weight loss following bariatric surgery have been limited
by clinical utility, and sensitivity and specificity [38,39].
Some data identifying potential markers of weight loss
are inadequately controlled and unmatched [38]. The
positive findings are in the context of complex interac-
tions, without clinically usable tests that could be applied
in daily practice [39].
While there is some potential in this field, usable tech-
niques are still many years away [40].
The factors most consistently negatively associated with
post-operative weight loss include higher BMI levels and
personality disorders [32]. Given the impact of psychologi-
cal markers on outcomes, techniques such the artificial
neural network, which can incorporate psychological and
biological measurements, have been tested to predict sur-
gical outcomes [41]. Such techniques rely on established
data that have been shown to effect outcomes, but may
incorrectly predict response in as many as 30% of bariatric
surgery recipients [41]. These models are multi-factorial,
prone to bias and socio-cultural differences [41]. They are
also time-consuming and expensive [41]. As the techni-
ques are refined, we may develop a useful model that
could be employed in routine practice, although we have
not arrived at that point as of yet.
While weight loss remains difficult to predict, there are
increasing amounts of data on prediction of diabetes
remission. Markers of insulin secretion, such as C-peptide
may aid pre-operative prediction of diabetes remission
[42]. These results report an increased rate of diabetes
remission with higher C-peptide levels [42,43]. The highest
cut-off can predict diabetes remission with a specificity of
approximately 90% [42]. Shorter duration of diabetes,
lower glycosylated hemoglobin (HbA1c) levels and insulin
independence are also associated with a higher post-opera-
tive remission rate [43,44]. These data illustrate a role for
C-peptide to be used in conjunction with clinical data to
predict diabetes remission. If a validated, sensitive and spe-
cific model were developed then it may aid procedure
selection. However, the models currently studied can pro-
vide great specificity, but only at the cost of sensitivity
[45].
The use of incretin and bile acid profiles has been inves-
tigated for use in predicting weight loss and metabolic
outcomes following bariatric surgery [46,47]. The findings
suggest that the restoration of peptide YY (PYY) and glu-
cagon-like-peptide- 1 (GLP-1) secretion following RYGB
contribute to satiety and weight loss [46,48]. Bile acids
also have a role in this process, and the mechanisms
underlying this are currently being elucidated [47].
Increased bile acid delivery to the terminal ileum can
improve satiety and enhance weight loss [47]. However,
these changes occur after surgery, and there is no current
evidence that would allow them to be used to select candi-
dates pre-procedure.
Similarly, while the restoration of the PYY and GLP-1
response is associated with satiety and weight loss in
RYGB, as opposed to AGB, there are no strong data on
differences within this group that allow us to predict the
degree of weight loss following RYGB based on the incre-
tin or bile acid response [48,49]. There are data demon-
strating a progressive rise in PYY and GLP-1 following
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RYGB that is associated with increased satiety but without
noted differences within the group [49]. The relationship
between absolute incretin or bile acid levels, or trends, and
weight loss remains to be determined. At this time, the
restoration of incretin secretion and increased serum levels
of bile acid are associated with enhanced satiety and
weight loss, but they cannot be used to predict weight loss
[46-49].
Procedure selection
For now, procedure selection is best informed by the can-
didates’ objectives and by how they want to live their
lives after surgery. As a primary aim of surgery, the effi-
cacy of weight loss associated with each procedure must
be considered. RYGB results in greater weight loss than
AGB, although good quality post-operative care can
improve the weight loss following AGB, with results
comparable to RYGB [50-52]. AGB is associated with a
lower rate of immediate post-operative complications but
also a higher rate of re-operation for insufficient weight
loss [50-52]. The associated mortality rate is higher with
RYGB than with AGB but still less than 0.3% [50,51].
Weight loss is comparable between RYGB and SG in
the short term [53,54]. Some studies suggest that more
patients will regain weight in the medium-term after SG
[55]. BPD/BPD-DS results in greater weight loss, but
with higher complication rates, than RYGB [56,57].
Therefore, the greatest weight loss would likely be
achieved with BPD/BPD-DS. However, this is not gener-
ally agreed. BPD/BPD-DS may not be suitable for high-
risk operative candidates and some randomized con-
trolled trials have shown no additional benefit of the
extra weight loss above RYGB [58].
There are variances in outcome between national
health systems, with AGB considered a superior bariatric
procedure in systems where there is an excellent post-
operative care pathway [52]. This implies that AGB can
have comparable results providing that the post-operative
care is planned and provided by experienced clinicians.
With regard to diabetes remission or treatment, RYGB
offers a greater rate of remission than AGB [50,51]. SG
has a remission rate comparable to RYGB in the short-
term, but a higher rate of relapse in the medium-term
[59]. BPD and BPD-DS may offer a higher rate of dia-
betes remission than RYGB or AGB [60-62]. While AGB
is the least effective in inducing diabetes remission, it can
offer substantial improvements in diabetes control, which
are greater than those offered by medical therapy in
obese cohorts [63,64].
Other conditions can influence a decision on bariatric
surgery. Respiratory disease may improve more signifi-
cantly with greater weight loss [65]. Therefore, those
with obstructive sleep apnea (OSA) or asthma could the-
oretically be considered for more consistently efficacious
procedures such as BPD/BPD-DS or RYGB. Conversely,
SG and AGB are associated with deteriorations in gastro-
esophageal reflux disease (GERD) and, therefore, should
be avoided in this cohort [55,66]. In GERD, RYGB is
increasingly considered as the treatment of choice as it
can remediate the GERD due to the reduction in the sto-
mach pouch and prevention of esophageal reflux [67].
In summary, candidate selection and preparation is key
to achieving good surgical outcomes. Each procedure
should be considered for each individual, and the data to
date do not support the application of a generic selection
based on body weight, diabetes or other co-morbidities.
The choice of procedure is a complex process with the
patient and their interests at its core. The surgeon’s
experience to deal with the inevitable complications of
each procedure and to manage long-term follow-up care
remain dominant considerations.
In those with diabetes, BPD/BPD-DS offers the highest
rate of remission, but also the highest complication rates.
RYGB and SG are comparably efficacious in treating dia-
betes in the short-term, but questions remain regarding
the medium to long-term. It should be noted that the
volume of data for RYGB is greater than that for SG and
BPD/BPD-DS. For those with GERD, RYGB should be
the treatment of choice. SG and AGB should be avoided.
AGB can also lead to weight loss and diabetes remission
and can offer greater control than medical therapy, even if
remission is not achieved. It should be noted that the
choice of AGB should take into account the availability of
good quality post-operative care. AGB may be suitable for
those who wish to lose weight and improve diabetes con-
trol, but not remission, and are at higher surgical risk.
Clinical outcomes
The outcomes following bariatric surgery vary between
procedures, and predicting individual outcomes following
bariatric surgery is difficult, for the reasons outlined in
the previous sub-sections. We will review each outcome
individually and compare between modalities below.
A. Airway: Obstructive sleep apnea (OSA) and asthma
Bariatric surgery is associated with impressive remission
rates for OSA (68). However, bariatric surgery can
improve the severity of OSA more frequently than result-
ing in full remission, and the improvement can still leave
the individual in a moderate or severe category [68]. The
symptoms of asthma can improve after bariatric surgery
but the mechanism of this effect is unknown, although
reduction of subcutaneous tissue with improvement of the
restrictive effect on the chest wall may be involved [69].
B. Body weight
Bariatric surgery effectively induces weight loss, but the
degree varies between procedures [8-10]. RYGB results in
greater weight loss than AGB in most studies [51]. The
quality of the post-operative care affects weight loss after
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AGB, with good quality post-operative care resulting in
comparable weight loss to RYGB [52]. Weight loss is
comparable between RYGB and SG at 36 months post-
operatively but long-term data are pending [53]. Weight
regain can be frequent following SG [55]. BPD results in
greater weight loss, but higher complication rates, than
RYGB, with comparable metabolic and quality of life out-
comes [56,58].
Weight loss usually reaches a maximum twelve months
post-operatively, and some weight regain is common
thereafter. The mean ten-year weight reduction is 25%
for RYGB and 13% for AGB [4].
C. Cardiovascular and cardiac disease
Obesity is a risk factor for cardiovascular disease [70]. The
available data over a median of almost twenty years show
that bariatric surgery is associated with reduced cardiovas-
cular mortality and morbidity [71]. In RYGB a reduction
of cardiovascular morbidity of more than 50% is seen
when compared to BMI and age matched controls [6,71].
The mechanism is unclear but improvements in glucose
metabolism, blood lipid profiles and hypertension prob-
ably contribute [71,72]. The reduction in hypertension and
dyslipidemia does remit somewhat post-operatively but
both remain reduced from baseline at ten years [6,7].
Cardiomyopathy in obesity is associated with left ven-
tricular hypertrophy and diastolic dysfunction with a
longer exposure to obesity associated with worse cardiac
function and larger ventricular mass [73]. Left atrial
dilatation and systolic dysfunction can also develop [74].
This is likely due to a combination of increased cardiac
output and increased circulatory volume [74]. Bariatric
surgery has been shown to result in improved cardiac
function and ‘reverse remodeling’ of the left ventricle up
to three years post-operatively [75].
D. Diabetes
There is a strong association between obesity and dia-
betes with approximately half of those diagnosed with
T2DM classified as obese [76]. Bariatric surgery can
induce remission of diabetes by inducing weight loss
[61]. There are also enteroendocrine effects following
RYGB and BPD, achieving greater remission rates for
diabetes when compared to patients who have had simi-
lar weight loss after AGB [61]. Diabetes remission is
greatest for patients undergoing BPD-DS, followed by
RYGB and then AGB [61]. SG has a comparable remis-
sion rate to RYGB [59,77]. The remission of diabetes
following bariatric surgery can be transient, with 72%
free of diabetes two years after bariatric surgery but only
36% remaining free of diabetes at ten years [4].
The most reliable long-term prospective data comes
from the Swedish Obese Study in which the majority of
participants underwent vertical banded gastroplasty with
the remaining undergoing RYGB or AGB [4]. Subgroup
analyses report that the RYGB group (N = 34) had a
greater reduction in serum glucose at ten years than the
rest of the cohort (N = 608) [4]. However, rates of dia-
betes according to subgroup and other prospective data
for RYGB specifically are not available. Retrospective
data at nine years following RYGB show a reduced rate
of medical treatment of diabetes by more than 65% in
parallel with a reduction in mortality of more than 70%
[78]. The improvement in mortality was primarily due
to a decrease in the number of cardiovascular deaths.
Shorter duration of diabetes, lower HbA1c levels and
insulin independence are associated with a higher post-
operative remission rate [44].
The presence of diabetes could influence the choice of
bariatric procedure with RYGB, BPD and SG considered
to result in remission of diabetes in a significant propor-
tion of candidates. In those who do not achieve remission,
bariatric surgery, including AGB, results in better glycemic
control and a reduced medication burden compared to
medical treatment [63,64]. Emerging data also suggest that
bariatric surgery may facilitate remission of microvascular
complications, such as microalbuminuria [79].
E. Economic
Obese individuals are more than twice as likely to take
sick leave and almost three times as likely to avail of dis-
ability benefits [4]. Medical costs are significantly higher
for obese individuals, mainly due to the cost of diabetic,
hypertensive and lipid therapy, but with additional costs
secondary to analgesia, respiratory and psychiatric treat-
ments [80,81]. When classified by BMI, patients in the
highest ranges spend more on healthcare [81].
While the presence of obesity may be secondary to
lower socio-economic status rather than causative, baria-
tric surgery has been shown to result in increased pro-
ductivity and reduced sick leave [82,83]. It is more costly
than non-surgical management of obesity in the short-
term but a return of investment can be achieved within
four years [84].
Medication prescription is reduced by bariatric surgery
with resultant reductions in healthcare costs that can
persist for up to 20 years [84,85]. Cost effectiveness may
also be achieved through reduced healthcare system uti-
lity due to the reduction in obesity related co-morbidities
[85]. However, the modeling used in this type of cost
assessment is open to criticism and there is a dearth of
controlled prospective data.
F. Functional
Basic activities of daily living such as walking and perso-
nal hygiene can be affected by severe obesity, and this
loss of autonomy can be extremely distressing for the
affected individuals [86]. Joint pain, including lower back
pain, is common in obese populations and can impinge
on individual functional status [87]. Bariatric surgery
results in improved function status, reduced levels of
back pain and greater levels of independence [87].
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G. Gonadal function and fertility
In men, obesity can result in erectile dysfunction,
reduced serum testosterone levels and reduced sperm
quality [88,89]. Bariatric surgery is associated with
increased serum testosterone levels but may paradoxi-
cally result in a deterioration in sperm quality [90,91].
There are no controlled prospective data to evaluate the
effect of bariatric surgery on male fertility.
In women, obesity is associated with high rates of ovula-
tory dysfunction, increased risk of spontaneous abortion
and increased materno-fetal risk in pregnancy [92]. There
is evidence that weight reduction via bariatric surgery can
improve ovulatory cycles and reduce hyperandrogenism in
women [93]. It also probably reduces materno-fetal risk,
although the current evidence is mainly limited to obser-
vational data [94,95]. To date, there are no randomized
controlled data or long-term prospective data available
and, therefore, no strong recommendation can be made
on advising reproductively active women considering bar-
iatric surgery.
H. Perceived health status
People who are classified as obese often report poor health
perceptions and altered mood [96]. Psychiatric co-morbid-
ities including anxiety and depression are also common
[97]. Bariatric surgery improves quality of life and per-
ceived health status, with changes seen in the first year
and benefit retained up to ten years [96]. Depression,
aggression and low self-concept can all be improved by
bariatric surgery [97]. The improvements in perceived
health status and quality of life may be correlated with
weight loss, with superior results following RYGB com-
pared to AGB [98]. However, factors other than weight
loss may be responsible for these psychological benefits as
the improvements have been reported in the immediate
post-surgical phase [99].
I. Image
Body image dysphoria is found in high frequency in obese
cohorts but this sometimes improves post-operatively
[86,100]. The improvement in body image satisfaction is
associated with improved quality of life scores, and the
improvements continue for at least two years following
surgery [101,102]. Weight regain is associated with dete-
rioration in self-concept and body image and can be asso-
ciated with depressive symptoms [102]. In general,
changes in body image are very unpredictable.
Eating disorders are common in obese populations [101].
Some evidence suggests that bariatric surgery can be asso-
ciated with remission of eating disorders, particularly binge
eating disorder [103]. The persistence of these disorders is
associated with poor outcomes, and eating behavior needs
to be regularly reviewed post-operatively [103].
J. Junction of gastro-esophagus
The presence of obesity and GERD has been linked with
pre-malignant metaplasia of the gastro-esophageal
junction, and frank adenocarcinoma of the esophagus
[104]. RYGB can reduce the symptoms of GERD and is
associated with regression of pre- malignant metaplasia
[67,105]. There is concern that AGB may worsen symp-
toms in a significant proportion of recipients [66]. SG has
also been associated with worsening GERD, and patients
with pre-existing disease may not be suitable candidates
[55].
Surgical treatment of GERD can be ineffective in obese
populations, and RYGB can be considered before fundo-
plication in this group given the improved outcomes
[67]. Therefore, the presence of GERD supports use of
RYGB as a first line procedure.
K. Kidney function
While the measurement of glomerular filtration rate in
obese cohorts is not well validated, obesity is noted to
result in higher rates of chronic kidney disease (CKD)
independent of the effect of co-morbid diabetes mellitus,
hypertension or dyslipidemia [106,107]. Renal parameters
such as serum creatinine and urinary protein excretion
can improve after bariatric surgery, but at present it is
unknown if the potential benefits outweigh the risks in
those with CKD, given the greater peri-operative risk
associated with renal impairment [29,108,109].
L. Liver
Liver disease such as hepatosteatosis, non-alcoholic stea-
tohepatitis (NASH), hepatic fibrosis, and cirrhosis are all
associated with obesity [110]. Bariatric surgery improves
the histological appearance of the liver and can lead to
regression of established liver disease [111]. However,
these data are often uncontrolled and some authors
have reported worsening in fibrosis rates after bariatric
surgery [111]. The presence of fibrotic liver disease
needs to be considered in the decision to proceed with
surgery and in follow-up plans post-operatively.
M. Medication
Bariatric surgery results in a significant cost reduction in
glycemic, lipid and antihypertensive therapy that can
take effect within two weeks of surgery [84,85]. There
are additional therapies needed following bariatric sur-
gery, with increased prescription of GERD therapy with
some procedures [80]. The need for increased GERD
treatment and ongoing mineral and vitamin supplemen-
tation can partially offset the cost reductions in diabetic
and cardiovascular medication [80,85].
O. Other
There is emerging evidence that weight loss using baria-
tric surgery may reduce the incidence of cancer [112]. It
seems that the protective effect is strongest for women,
and the reduction of risk may be as high as 60%
[6,112,113]. The mechanisms underlying this apparent
risk reduction are unclear, but may involve mediation of
inflammatory pathways and attenuation of obesity asso-
ciated hyperinsulinism [112].
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Morbidity and mortality after bariatric surgery
Surgical complications can be defined as early or late,
depending on if they occur within the first thirty post-
operative days or afterwards. There is a wide range in
the reported complication rates. The benchmark for bar-
iatric centers of excellence is the Longitudinal Assess-
ment of Bariatric Surgery consortium [114]. Mortality
rates after bariatric surgery are low with a mortality rate
after RYGB of 0.3% [114]. Pulmonary and venous
thrombo-embolism are early complications and occur in
less than 0.5% of bariatric surgery recipients [115].
Other complications can be specific to the modality and
include the following.
1. Anastomotic leak and bowel perforation
Anastomotic leak is a feared early complication. Higher
BMI, male gender, re-operation, older age and surgeon’s
experience are all associated with higher rates of anasto-
motic leakage [115,116]. Leakage can occur at any of the
anastomotic junctions in RYGB, SG or BPD/BPD-DS and
can result in severe peritonitis, sepsis, and multi-organ
failure. Enteric leaks require emergent operative treat-
ment in the context of hemodynamic instability or
peritonitis.
Anastomotic leakage appears most commonly at the
gastrojejunostomy in RYGB and the incidence associated
with mortality is 0.1% [116,117]. The incidence of leakage
is up to 3.6% in SG and most commonly occurs as a
defect in the staple line [118]. In BPD-DS, leakage from
the staple line is more common than anastomotic leakage
and the total enteric leakage rate is 5% [119].
In AGB, there is no anastomosis and gastro-esopha-
geal perforation is an uncommon early complication
that can result in peritonitis and abdominal sepsis with
an incidence of less than 0.5% [120].
2. Hemorrhage
Hemorrhage is an early complication that occurs in up to
4% of patients [121]. Using finer anastomotic closure
techniques can reduce bleeding rates [122]. The presence
of diabetes mellitus has been associated with a higher
risk of post-operative hemorrhage [123]. In SG, hemor-
rhage has an incidence of up to 5.6%, but there is a large
range in reported data that is likely explained by surgical
experience, the complexity of the case intra-operatively,
and the use of buttress material [124,125].
3. Bowel obstruction
Internal hernias can cause bowel obstruction, and can
occur early or late post-operatively. The reported fre-
quency ranges from 0.4% to 5.5% in RYGB [126,127].
Long-term data over seven years record a hernia rate of
38% in BPD/BPD-DS [128]. A laparoscopic approach may
result in higher rates, but new surgical techniques where
the mesentery windows are surgically closed may reduce
the rate to as low as 1% [129].
4. Anastomotic stricture
Anastomotic stricture is a late complication that can occur
at any of the anastomotic sites. It is commonly described
at the gastrojejunostomy in RYGB and is associated with
dysphagia and vomiting [130]. The mean incidence of gas-
trojejunal stricture is approximately 10%, but rates as high
as 20% are reported [130]. The laparoscopic approach and
use of circular staplers to make the gastrojejunal anasto-
mosis may result in higher rates of stricture [131].
5. Other complications
Incisional hernias can occur but are less common with the
increased use of laparoscopic techniques [10]. Marginal
ulcers are usually late complications of bariatric surgery
and occur in 2% of patients within the first post-operative
year, and then in 0.5% for up to five years [132]. Proton
pump inhibition is the preferred treatment but ulcers can
be refractory and may require revisional surgery [133].
6. Complications specific to AGB
Band migration is becoming less common since the intro-
duction of the ‘pars flaccida’ technique and individually
sized bands, with rates as low as 1.4% [134]. Band migra-
tion can result in acute postoperative stoma obstruction,
although this can occur in the absence of migration due to
impacted food boluses [135].
Infections of the adjustment port can be an early or late
complication. A late adjustment port infection can present
years post-operatively, with abdominal pain or port site
erythema, caused by band erosion with ascending infec-
tion, in up to 1% of cases [136]. This can result in intra-
abdominal sepsis requiring removal of the band and high
dose intravenous antibiotics. Band erosion is associated
with surgical experience, with higher rates in those with
less experience [137].
There is a recognition that AGB can have high failure
rates in long-term follow-up, although this can likely be
remediated by good quality post-operative care [138,139].
The emergence of SG as a procedure with greater weight
loss and metabolic effects than AGB, with complication
rates comparable or possibly slightly lower than RYGB has
led to the consideration of SG before AGB in some cases
[139]. However, SG’s major Achilles heel is the lack of long-
term data with some authors concerned that the 10-year re-
operation rate after SG will be similar to that of AGB.
As long-term data accumulate, SG may come to
replace AGB in many cases, although for now AGB is
likely to remain more popular given the established
experience in its use and the lower complication rate in
comparison to the other major bariatric modalities [139].
Nutritional and gastrointestinal complications after
bariatric surgery
Deficiencies of iron, vitamin B12, folate, and fat-soluble
vitamins can occur after bariatric surgery and are best
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described in RYGB, BPD and BPD-DS [140]. Vitamin D
deficiency can persist despite prescribed replacement in
BPD and may tend towards secondary hyperparathyroid-
ism [140]. The risk of nutritional deficiencies depends on
postoperative weight loss, the surgical procedure per-
formed and patient compliance with follow up [140,141].
Vomiting is frequent after bariatric surgery but must
always be considered to be pathological until proven
otherwise after RYGB. An examination and appropriate
radiological studies to screen for stricture, stoma stenosis
or herniation must be completed. If no pathological
cause is found then treatment should be conservative
with replacement of fluid and electrolytes [141]. Often,
vomiting can be the result of overeating or rapid eating.
The patient should be re-educated on eating habits and
kept under review.
Diarrhea is reported in up to 40% following bariatric
surgery [142]. More than 30% of bariatric surgical recipi-
ents report worsening bowel function in the post-operative
period and some develop fecal incontinence [143].
The etiology of this is unclear and treatment is based on
appropriate dietary modification and anti-diarrheal
pharmacotherapy.
There is a variable incidence of the dumping syn-
drome after bariatric surgery, particularly in RYGB
[144]. Dumping syndrome remains a ‘waste-basket diag-
nosis’, with the clinical presentation generally considered
to include early abdominal pain, diarrhea, nausea, bloat-
ing, fatigue, facial flushing, palpitations, hypotension and
syncope after high glycemic index meals. These symp-
toms usually occur within an hour of eating. Similar
symptoms that occur two or three hours after a meal
include perspiration, palpitations, hunger, tremor, agita-
tion, and syncope [144]. These have been blamed on
hypoglycemia and GLP-1, although a definitive etiology
remains to be established [145,146].
The treatment of early dumping syndrome is usually
straightforward dietary modification, with small regular
meals containing protein and carbohydrate with a very
low glycemic index. Treatment of the symptoms that
occur within two or three hours of a meal also rely on the
same dietary modifications, with the added aim of 2 or 3
kg of weight gain which often abolishes the symptoms sec-
ondary to the small amount of increased insulin resistance.
Pharmacotherapy with acarbose or somatostatin analogues
may be needed [147], with transient enteral feeding
required in severe cases [144].
There is some overlap in the hypoglycemic syndromes
associated with bariatric surgery, with a number of
mechanisms likely contributing to each. Obesity-related
beta-cell hypertrophy that does not fully regress after
weight loss, with improved GLP-1 dynamics and improved
peripheral sensitivity, all probably contribute to each syn-
drome [148]. There can be an exaggerated incretin
response in those with hypoglycemic syndromes [145,146].
However, the extent to which the incretin effect is
involved can vary by syndrome and even by case [148]. If a
post-operative patient presents with dumping syndrome
or hypoglycemia that is unresponsive to dietary modifica-
tion or 3 kg weight gain, or with atypical features such as
fasting symptoms, then a full investigation of their insulin
dynamics is needed.
Other complications after bariatric surgery
Other post-operative complications include alopecia,
cholelithiasis and hypoglycemia. Postoperative hair loss
has been reported in up to 4.5% of bariatric surgical can-
didates [149]. This is usually mild and non-progressive.
Cholelithiasis can occur in up to 2% of individuals in the
months after surgery [150]. Ursodeoxycholic acid has
been recommended for prevention [140].
Future directions
As obesity continues to become more prevalent, bariatric
surgery will become necessary for greater numbers of peo-
ple. The current guidelines are aimed at a grade of obesity
considered moderate to severe, but evidence is accumulat-
ing for the use of bariatric surgery in those with BMI levels
of less than 35 kg/m2 [151]. This is particularly the case in
those with diabetes [151].
The ongoing randomized controlled trials comparing
bariatric surgery and intensive medical glycemic therapy
may yield results that will lead to bariatric surgery being
used for metabolic benefits in those with diabetes,
including those with BMIs of less than 35 kg/m2
[63,64]. This is the continuation of the concept of meta-
bolic surgery; the idea that bariatric procedures should
have a primary goal of inducing remission of metabolic
diseases, such as diabetes. However, this concept
remains controversial, and further data need to be col-
lected to determine the benefits of this approach.
Finally, the goal of individualizing bariatric treatment
and predicting response remains challenging. The work
on genotyping and predictive models is ongoing but
usable models remain elusive. Evidence to date suggests
that the factors most predictive of weight loss may be
psychological [32]. As genome association data are gath-
ered we may identify genes that can allow us to tailor
the bariatric approach to the individual [36,37,152,153].
However, given the expense associated with this tech-
nology, its clinical utility at present is low and clinical
evaluation will remain the mainstay of pre-operative
assessment and procedure selection.
Conclusions
Bariatric surgery should be considered in individuals
with a BMI of greater than 40 kg/m2 and in those with
a BMI of more than 35 kg/m2 and obesity related co-
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morbidities. In future, guidelines may recommend sur-
gery for those with BMIs of less than 35 kg/m2 with dia-
betes or other metabolic disease.
Not all candidates are suitable to proceed to surgery,
and an experienced multi- disciplinary assessment is
essential to select the appropriate candidates. The choice
of surgical modality should take the individual’s goals,
surgeon’s experience and existing co-morbidities into
account. Individualizing care is central to the assessment,
and this is determined by clinical evaluation rather than
using predictive models, genotyping or biomarkers at
present.
Bariatric surgery performed in experienced centers has a
low complication rate and leads to long-term weight loss,
with associated functional, metabolic and psychological
improvements. Bariatric procedures are effective in treating
and preventing many obesity related co-morbidities. Long-
term follow-up is mandatory to support a safe outcome.
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